US FoodDrug Administration (FDA)
® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK ...
As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). Tony Mok, MD As a first-line treatment, crizotinib (Xalk...
®(ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK ...
Center, Toranomon Hospital, Tokyo, Japan; 2Department of Pathology, Massachusetts General Hospital, Boston, MA, USA Abstract: Screening for anaplastic lymphoma kinase (ALK) rearrangements is a very impor- tant process in treatment decision making for advanced non-small-cell lung cancer (NSCLC). Alt...
AlthoughALKrearrangement is only found in a small portion of NSCLC patients, because lung cancer is so common, the number of patients who stand to benefit is substantial — 4% to 5% of all patients with NSCLC is about 8,000 to 10,000 patients each year in the United States, Dr. Shaw ...
June 3, 2013 — The targeted agentcrizotinib(Xalkori) is superior to standard chemotherapy in patients with previously treated advanced nonsmall-cell lung cancer (NSCLC) and anaplasticlymphomakinase (ALK) gene rearrangement, according to a phase 3 open-label trialpublished onlineJune 1 in theNew En...
Background: Crizotinib is a novel thyrosine kinase inhibitor for patients with advanced non-small cell lung cancer (NSCLC) harboring EML4-ALK fusion gene. The frequency of the ALK fusion gene is around 5% in all lung cancer in Japan. Because crizotinib has been launched last year and ALK-po...
Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We investigated whether continuing ALK inhibition with crizotinib beyond PD (CBPD) is clinically beneficial and attempted to identify clinicopathologic...
EP: 2.Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial EP: 3.Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer E...